StockTipsArenaBeta

BUY Lupin Limited — BOB Capital Markets

BUYLupin Limited

byBOB Capital MarketsHorizon: NA (inferred 1 year)4 Sept 2025via Institutional / Brokerage Research

Entry₹1,939.2Inferred
Target₹2,626
Total upside +35.42% (call closed)
Stop lossNot given
At expiry₹2,1104 Sept 2026, 3:30 pm
Expired+8.81%auction close
Follow BOB Capital Markets for new calls(63% target hit, 356 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 14 active Long-term calls on LUPINSee 40 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Sept 2026
43 supporting3 neutral10 opposing
Supports the BUY call (43)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Aug · 6d ago

8 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 1w ago

Lupin wins ruling on Vertex patents for cystic fibrosis drug

NewsCnbc-Tv18·26 Aug · 1w ago

(opens in new tab)

Lupin arm gets exclusive rights to presbyopia treatement drug in Europe

NewsCnbc-Tv18·20 Aug · 2w ago

(opens in new tab)

Lupin Ltd's wholly owned subsidiary, VISUfarma B.V., has entered into an Exclusive License Agreement with Visus Therapeutics, Inc.

BSE · Company Update·20 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (3)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (10)

Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050

NewsEt-Markets·27 Aug · 1w ago

(opens in new tab)

Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive

NewsCnbc-Tv18·27 Aug · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.